Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V110 (Pneumovax 23) in Russian Population
NCT01734239Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Primary completion
- Oct 2013
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Merck & Co.. Started Jun 2013; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT01734239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734239.